1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Material Name: Ferrous Fumarate Tablets, 75 mg (Packaged with Estrostep Fe and Loestrin Fe)

| Trade Name: | Not established |
| Chemical Family: | Mixture |
| Intended Use: | Pharmaceutical active used as dietary supplement |

2. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS List</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ferrous fumarate</td>
<td>141-01-5</td>
<td>205-447-7</td>
<td>60.8</td>
</tr>
<tr>
<td>Microcrystalline cellulose</td>
<td>9004-34-6</td>
<td>232-674-9</td>
<td>*</td>
</tr>
<tr>
<td>Sucrose</td>
<td>57-50-1</td>
<td>200-334-9</td>
<td>*</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>209-150-3</td>
<td>*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS List</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maltodextrin</td>
<td>9050-36-6</td>
<td>232-940-4</td>
<td>*</td>
</tr>
<tr>
<td>Sodium starch glycolate</td>
<td>9063-38-1</td>
<td>Not listed</td>
<td>*</td>
</tr>
<tr>
<td>Povidone</td>
<td>9003-39-8</td>
<td>Not listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information: * Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

3. HAZARDS IDENTIFICATION

Appearance: Brown tablets

Statement of Hazard: Non-hazardous in accordance with international standards for workplace safety.

Additional Hazard Information:
Short Term: Dust may cause irritation. Not acutely toxic (based on animal data)
Known Clinical Effects: The most immediate effect seen after ingestion of iron is GI irritation which may lead to nausea, vomiting, and other GI effects. Excessive ingestion/overdose may result in more serious side effects, including death.

EU Indication of danger: Not classified
Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

4. FIRST AID MEASURES

Eye Contact: Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.

Skin Contact: Remove clothing and wash affected skin with soap and water. This material may not be completely removed by conventional laundering. Consult professional laundry service. Do not home launder. If irritation occurs or persists, get medical attention.

Ingestion: Get medical attention. Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person.

Inhalation: Remove to fresh air. If not breathing, give artificial respiration. Get medical attention.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: No data available

Fire Fighting Procedures: Wear approved positive pressure, self-contained breathing apparatus and full protective turn out gear.

Fire / Explosion Hazards: Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing.

Storage Conditions: Store in a cool, dry place away from direct sunlight.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Ferrous fumarate
MATERIAL SAFETY DATA SHEET

Material Name: Ferrous Fumarate Tablets, 75 mg (Packaged with Estrostep Fe and Loestrin Fe)
Revision date: 02-Jan-2007

9. PHYSICAL AND CHEMICAL PROPERTIES:

<table>
<thead>
<tr>
<th>Physical State:</th>
<th>Tablet</th>
<th>Color:</th>
<th>Brown</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular Formula:</td>
<td>Mixture</td>
<td>Molecular Weight:</td>
<td>Mixture</td>
</tr>
</tbody>
</table>

10. STABILITY AND REACTIVITY

Stability: Stable under normal conditions of use.
Conditions to Avoid: None known
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers.

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)
Acute Toxicity Comments:
A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Inhalation Acute Toxicity
Ferrous fumarate may be irritating to the respiratory system.

Ingestion Acute Toxicity
See Acute toxicity table In humans 20 mg/kg of elemental iron may cause GI irritation and 60 mg/kg may lead to systemic toxicity.

Irritation / Sensitization: (Study Type, Species, Severity)

Microcrystalline cellulose
Skin Irritation Rabbit Non-irritating
Eye Irritation Rabbit Non-irritating
Eye Irritation / Sensitization Ferrous fumarate may be irritating to the eyes.
Skin Irritation / Sensitization No data available
Chronic Toxicity Chronic ingestion of iron preparations may cause GI tract irritation with nausea, vomiting, heartburn, anorexia, constipation, and diarrhea. Chronic excessive iron intake may cause damage to the liver and pancreas.

Reproductive Effects
High level exposures to iron (maternally toxic doses) have been associated with spontaneous abortions and preterm delivery. Data on these exposures are equivocal and limited. Iron overload has been associated with reduced spermatogenesis in male rats.

Teratogenicity
Large dose dietary iron supplements were not teratogenic when tested in mice and rats. Pregnant rabbits fed maternally toxic doses of an iron supplement had offspring with an increased incidence of defects of the CNS and skeleton.

Mutagenicity
No data available

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

Povidone
IARC: Group 3

12. ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this mixture have not been fully evaluated. Releases to the environment should be avoided.
13. DISPOSAL CONSIDERATIONS

Disposal Procedures:
Dispose of waste in accordance with all applicable laws and regulations.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger: Not classified

OSHA Label:
Non-hazardous in accordance with international standards for workplace safety.

Canada - WHMIS: Classifications

WHMIS hazard class:
None required
This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Ferrous fumarate
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- Standard for the Uniform Scheduling for Drugs and Poisons:
  - Schedule 2
  - Schedule 4
  - Schedule 5
  - Schedule 6
- EU EINECS List: 205-447-7

Maltodextrin
- Inventory - United States TSCA - Sect. 8(b): XU
- Australia (AICS): Present
- EU EINECS List: 232-940-4

Sodium starch glycolate
- Inventory - United States TSCA - Sect. 8(b): XU
- Australia (AICS): Present

Microcrystalline cellulose
- Inventory - United States TSCA - Sect. 8(b): XU
- Australia (AICS): Present
16. OTHER INFORMATION

Reasons for Revision: Updated Section 3 - Hazard Identification. Updated Section 6 - Accidental Release Measures. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 10 - Stability and Reactivity. Updated Section 11 - Toxicology Information. Updated Section 13 - Disposal Considerations. Updated Section 15 - Regulatory Information.

Prepared by: Toxicology and Hazard Communication
             Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied.

End of Safety Data Sheet